Free Trial

Belite Bio (BLTE) Competitors

$45.57
0.00 (0.00%)
(As of 05/24/2024 ET)

BLTE vs. KNSA, GMTX, ANIP, DAWN, MNKD, PCRX, SYRE, XNCR, MORF, and MIRM

Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), MannKind (MNKD), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Xencor (XNCR), Morphic (MORF), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical preparations" industry.

Belite Bio vs.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.

Kiniksa Pharmaceuticals received 143 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.83% of users gave Belite Bio an outperform vote while only 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Kiniksa PharmaceuticalsOutperform Votes
166
64.34%
Underperform Votes
92
35.66%
Belite BioOutperform Votes
23
95.83%
Underperform Votes
1
4.17%

Kiniksa Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals$270.26M5.00$14.08M$0.11173.20
Belite BioN/AN/A-$31.63M-$1.18-38.62

Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Kiniksa Pharmaceuticals' net margin of 0.00%. Belite Bio's return on equity of -7.26% beat Kiniksa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals2.78% -7.26% -6.09%
Belite Bio N/A -44.15%-41.53%

54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.52, meaning that its share price is 252% less volatile than the S&P 500.

Kiniksa Pharmaceuticals currently has a consensus price target of $31.00, indicating a potential upside of 62.73%. Belite Bio has a consensus price target of $44.83, indicating a potential downside of 1.62%. Given Belite Bio's higher possible upside, equities research analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Belite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Belite Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Belite Bio had 8 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 11 mentions for Belite Bio and 3 mentions for Kiniksa Pharmaceuticals. Belite Bio's average media sentiment score of 0.27 beat Kiniksa Pharmaceuticals' score of 0.06 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Belite Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kiniksa Pharmaceuticals beats Belite Bio on 13 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLTE vs. The Competition

MetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.36B$6.81B$5.20B$8.06B
Dividend YieldN/A2.67%2.83%3.93%
P/E Ratio-38.6221.27152.1518.19
Price / SalesN/A259.912,464.4379.80
Price / CashN/A36.7936.3031.61
Price / Book14.065.865.444.60
Net Income-$31.63M$132.39M$106.24M$214.07M
7 Day Performance1.33%-2.40%-1.33%-1.08%
1 Month Performance22.27%1.64%2.76%3.20%
1 Year Performance95.83%-6.49%3.39%7.84%

Belite Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KNSA
Kiniksa Pharmaceuticals
1.6522 of 5 stars
$19.37
-1.5%
$31.00
+60.0%
+34.9%$1.37B$270.26M176.11297
GMTX
Gemini Therapeutics
0 of 5 stars
$32.37
+0.6%
N/A+0.5%$1.40BN/A-32.3731News Coverage
Positive News
ANIP
ANI Pharmaceuticals
4.6836 of 5 stars
$61.71
0.0%
$81.00
+31.3%
+31.4%$1.29B$486.82M38.57642Insider Selling
DAWN
Day One Biopharmaceuticals
2.4877 of 5 stars
$14.79
-7.4%
$37.67
+154.7%
+11.1%$1.29BN/A-5.89155Gap Down
MNKD
MannKind
3.0192 of 5 stars
$4.74
+0.9%
$8.00
+68.8%
+1.5%$1.29B$198.96M158.05411Insider Selling
PCRX
Pacira BioSciences
4.9236 of 5 stars
$30.90
+0.9%
$47.40
+53.4%
-26.8%$1.44B$674.98M21.61711Positive News
SYRE
Spyre Therapeutics
1.2023 of 5 stars
$36.09
-2.1%
$43.17
+19.6%
N/A$1.45B$890,000.00-0.5130Positive News
XNCR
Xencor
4.1471 of 5 stars
$23.77
+0.1%
$35.43
+49.0%
-15.0%$1.47B$168.34M-10.85280Gap Up
MORF
Morphic
3.7383 of 5 stars
$29.49
-3.0%
$51.50
+74.6%
-47.6%$1.48B$520,000.00-8.43121News Coverage
MIRM
Mirum Pharmaceuticals
4.4672 of 5 stars
$25.79
+1.9%
$49.73
+92.8%
-8.5%$1.22B$186.37M-6.95264

Related Companies and Tools

This page (NASDAQ:BLTE) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners